Targeting 20 lbs: Can Ozempic Help You Reach Your Weight Loss Goals?

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Twenty pounds is a reasonable goal, but Ozempic is not the semaglutide product the FDA approved to pursue it. According to the Ozempic prescribing information, the medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight management is not among them. Weight change was measured in the Ozempic trials, and it was real, but the average reductions reported in labeling fall short of twenty pounds — and the semaglutide product actually studied and approved for weight reduction is a different one.

Twenty Pounds Is a Percentage, Not a Number

Obesity medicine does not measure success in pounds, because a pound means something different depending on where you start. Every major weight trial reports percentage change in body weight, and every FDA labeling section for these drugs follows the same convention. Twenty pounds off a 200-pound starting weight is a 10 percent reduction. The same twenty pounds off 300 pounds is under 7 percent. Off 150 pounds it is more than 13 percent.

That matters because the published evidence is expressed in percentages, so translating a trial result into your twenty pounds requires knowing your own baseline. It also matters clinically: the health benefits documented in these trials — blood pressure, lipids, glycemic measures — track with proportional loss, not with absolute pounds.

So the honest version of the question is not "will this drug produce twenty pounds," but "what percentage of my body weight does twenty pounds represent, and what does the evidence say about reaching that percentage." Those are two different conversations, and only the second one has data behind it.

What the Ozempic Trials Actually Reported for Body Weight

Section 14 of the Ozempic label reports body weight as a secondary observation in trials whose primary endpoint was HbA1c reduction. In the monotherapy trial, mean change in body weight from baseline to week 30 was −1.2 kg with placebo, −3.8 kg with Ozempic 0.5 mg, and −4.7 kg with Ozempic 1 mg. The treatment differences from placebo were −2.6 kg and −3.5 kg respectively.

In the trial comparing the 2 mg dosage with 1 mg, mean body weight change from baseline to week 40 was −5.6 kg with 1 mg and −6.4 kg with 2 mg, and the label notes that the difference between the treatment arms in body weight change at week 40 was not statistically significant. Converted, those figures span roughly 8 to 14 pounds of average change.

Averages are not ceilings, and individual participants moved further in both directions. But if you are reading labeling to forecast twenty pounds, the labeling for Ozempic does not support that forecast, and it was never designed to.

The Semaglutide Product Studied for Weight Reduction

Wegovy, a higher-dose semaglutide product, was approved by the FDA on June 4, 2021. The Wegovy prescribing information now covers reduction of major adverse cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight, reduction of excess body weight and long-term maintenance of weight reduction in adults and pediatric patients 12 years and older, and, under accelerated approval, noncirrhotic MASH with moderate-to-advanced liver fibrosis.

The pivotal weight trial ran 68 weeks in adults with obesity or overweight who did not have type 2 diabetes. As reported in labeling, mean change in body weight was −14.9 percent with semaglutide 2.4 mg versus −2.4 percent with placebo. The published trial in the New England Journal of Medicine enrolled 1,961 adults and reported the same −14.9 percent versus −2.4 percent, with mean absolute change of −15.3 kg versus −2.6 kg — approximately 34 pounds versus about 6.

How Many People Reached Meaningful Thresholds

The distribution matters more than the mean. In the labeling for that 68-week trial, 83.5 percent of participants on semaglutide achieved at least 5 percent weight reduction versus 31.1 percent on placebo, 66.1 percent achieved at least 10 percent versus 12 percent, and 47.9 percent achieved at least 15 percent versus 4.8 percent.

Map that onto twenty pounds. If you weigh 200 pounds, twenty pounds is the 10 percent threshold — reached by about two-thirds of trial participants. If you weigh 250, twenty pounds is 8 percent, which sits between the 5 and 10 percent bands. If you weigh 160, twenty pounds is 12.5 percent, closer to the 15 percent band that fewer than half reached.

None of this predicts your result. It does show that "twenty pounds" is an easier or harder target depending entirely on your starting point, and that a substantial minority of trial participants did not reach even 5 percent.

Nothing in These Trials Tested the Medication Alone

Both the Ozempic and Wegovy indications are written as adjuncts — to diet and exercise in the case of Ozempic, and in combination with a reduced-calorie diet and increased physical activity in the case of Wegovy. The trial protocols enforced this. Participants in the 68-week weight trial received lifestyle intervention alongside the study drug in both arms, which is why the placebo group still lost 2.4 percent.

A separate 68-week trial, STEP 3, layered intensive behavioral therapy on top: 611 adults, 30 counseling visits, an initial low-calorie diet for eight weeks. Estimated mean body weight change was −16.0 percent with semaglutide 2.4 mg versus −5.7 percent with placebo, and 75.3 percent of the semaglutide group reached at least 10 percent.

Time Horizon Is Part of the Answer

The weight trials ran 68 weeks, and 16 of those weeks were dose escalation. Results are reported at the end of that period, not at week four or week twelve. Anyone benchmarking their own progress against a headline percentage is comparing against a year-and-a-quarter endpoint.

Duration also cuts the other way. In the STEP 1 trial extension, 327 participants were followed for a year after all treatment and lifestyle intervention were withdrawn. Those who had been on semaglutide regained 11.6 percentage points of the 17.3 percent they had lost, leaving a net 5.6 percent reduction at week 120. The authors concluded that ongoing treatment appears to be required to maintain the improvements.

Where Compounded Semaglutide Fits

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription written for an individual patient. Wegovy and Ozempic are the FDA-approved semaglutide brands, and a compounded preparation is not a generic version of either — neither brand has an approved generic equivalent.

PlexusDx dispenses through licensed 503A compounding pharmacies. Whether a compounded protocol is appropriate for you, and what a realistic target looks like given your starting weight and medical history, is a determination your prescriber makes — not one an article, a calculator, or a headline percentage can make for you.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic approved by the FDA for losing 20 pounds or any amount of weight?

No. The Ozempic prescribing information lists three indications, all of them in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. There is no weight-management indication in its labeling.

How much weight did people lose in the Ozempic trials?

Section 14 of the label reports body weight as a secondary observation in trials whose primary endpoint was HbA1c. In the monotherapy trial, mean change at week 30 was −3.8 kg with 0.5 mg and −4.7 kg with 1 mg, versus −1.2 kg with placebo. In the trial comparing 2 mg with 1 mg, mean change at week 40 was −6.4 kg and −5.6 kg respectively, a difference the label states was not statistically significant.

What percentage of my body weight is 20 pounds?

It depends entirely on your starting weight, which is why trials report percentages rather than pounds. Twenty pounds is 10 percent of 200, about 8 percent of 250, roughly 6.7 percent of 300, and 12.5 percent of 160. Because the published evidence and FDA labeling are both expressed as percentage change, you need your own baseline to translate any trial figure into a pound target that means something for you.

Which semaglutide product is approved for weight reduction?

Wegovy, approved June 4, 2021. Its labeling covers reducing major adverse cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight, reducing excess body weight and maintaining weight reduction long term in adults and patients 12 and older, and noncirrhotic MASH with moderate-to-advanced fibrosis under accelerated approval. In the 68-week pivotal trial, mean body weight change was −14.9 percent versus −2.4 percent with placebo.

Do results hold if treatment stops?

The STEP 1 trial extension followed 327 participants for a year after semaglutide and lifestyle intervention were both withdrawn. Mean loss during the 68-week treatment phase had been 17.3 percent; participants then regained 11.6 percentage points, ending at a net 5.6 percent reduction from baseline at week 120. Most cardiometabolic improvements also reverted toward baseline. The investigators concluded that ongoing treatment appears necessary to maintain results.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.